Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > WHEN WILL IT HALT FOR 8 MONTHS LIKE LAST TIME

<< Previous

Bullboard Posts

Next >>

Post by losingmyshirton Jun 08, 2022 8:04am

149 Views

Post# 34739453

WHEN WILL IT HALT FOR 8 MONTHS LIKE LAST TIME

For those of you who are not aware, Robert Farrell has pulled the same stunt before with Kalytera.

Exactly the same happened when Bob saw that his scam of GVHD ran out of steam.

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023